JP2009525051A5 - - Google Patents

Download PDF

Info

Publication number
JP2009525051A5
JP2009525051A5 JP2008553389A JP2008553389A JP2009525051A5 JP 2009525051 A5 JP2009525051 A5 JP 2009525051A5 JP 2008553389 A JP2008553389 A JP 2008553389A JP 2008553389 A JP2008553389 A JP 2008553389A JP 2009525051 A5 JP2009525051 A5 JP 2009525051A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hiv
peptide
circulating
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008553389A
Other languages
English (en)
Japanese (ja)
Other versions
JP4682251B2 (ja
JP2009525051A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/002990 external-priority patent/WO2007097903A2/en
Publication of JP2009525051A publication Critical patent/JP2009525051A/ja
Publication of JP2009525051A5 publication Critical patent/JP2009525051A5/ja
Application granted granted Critical
Publication of JP4682251B2 publication Critical patent/JP4682251B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008553389A 2006-02-02 2007-02-02 改善された生物学的特性を有するｈｉｖ融合阻害剤ペプチド Expired - Fee Related JP4682251B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76467406P 2006-02-02 2006-02-02
PCT/US2007/002990 WO2007097903A2 (en) 2006-02-02 2007-02-02 Hiv fusion inhibitor peptides with improved biological properties

Publications (3)

Publication Number Publication Date
JP2009525051A JP2009525051A (ja) 2009-07-09
JP2009525051A5 true JP2009525051A5 (enExample) 2010-03-18
JP4682251B2 JP4682251B2 (ja) 2011-05-11

Family

ID=38437849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008553389A Expired - Fee Related JP4682251B2 (ja) 2006-02-02 2007-02-02 改善された生物学的特性を有するｈｉｖ融合阻害剤ペプチド

Country Status (15)

Country Link
US (3) US7456251B2 (enExample)
EP (1) EP1989220B1 (enExample)
JP (1) JP4682251B2 (enExample)
CN (1) CN101415723B (enExample)
AR (2) AR059300A1 (enExample)
AT (1) ATE537183T1 (enExample)
AU (1) AU2007218025A1 (enExample)
CA (1) CA2651793C (enExample)
CY (1) CY1113115T1 (enExample)
DK (1) DK1989220T3 (enExample)
ES (1) ES2381631T3 (enExample)
NZ (1) NZ570300A (enExample)
PT (1) PT1989220E (enExample)
TW (1) TWI341844B (enExample)
WO (1) WO2007097903A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1989220T3 (da) 2006-02-02 2012-04-02 Trimeris Inc HIV-fusionsinhibitorpeptider med forbedrede biologiske egenskaber
CN101874038A (zh) * 2007-09-25 2010-10-27 特里梅里斯公司 治疗性抗-hiv肽的合成方法
AU2009260479A1 (en) * 2008-05-28 2009-12-23 New York Blood Center Bifunctional molecules for inhibiting HIV entry
EP2377880A3 (en) * 2008-08-13 2012-03-21 New York Blood Center Combination therapy of HIV fusion entry inhibitors targeting gp41
AU2009305577A1 (en) * 2008-10-16 2010-04-22 New York Blood Center Immunoenhancer-linked oligomeric HIV vaccines
WO2010047826A2 (en) * 2008-10-24 2010-04-29 Trimeris, Inc. Dosing regimens and dosage formulations of an antiviral peptide therapeutic
EP2393507A2 (en) * 2009-02-09 2011-12-14 New York Blood Center, Inc. Trimerich hiv fusion inhibitors for treating or preventing hiv infection
WO2011140092A1 (en) 2010-05-03 2011-11-10 New York Blood Center, Inc. Bifunctional molecules for inactivating hiv and blocking hiv
BR112014014917A2 (pt) * 2011-12-19 2018-05-15 Janssen R&D Ireland inibidores de fusão da membrana do hiv
US20150045291A1 (en) 2012-04-04 2015-02-12 Yeda Research And Development Co., Ltd. Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides
CN103724404B (zh) * 2013-12-08 2016-11-02 北京工业大学 抑制hiv病毒与宿主细胞融合的非对映体多肽及其用途
GB201509782D0 (en) * 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis
CN109320593A (zh) * 2018-11-05 2019-02-12 中国人民解放军军事科学院军事医学研究院 抑制hiv感染的螺旋多肽及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016273A (en) 1975-07-16 1977-04-05 American Cyanamid Company Sustained release forms of certain oxazepines for parenteral administration
JPS55154991A (en) 1979-05-23 1980-12-02 Hisamitsu Pharmaceut Co Inc Beta-d-fructopyranoside derivative
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US5411951A (en) 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US4629783A (en) 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US5234520A (en) 1987-03-20 1993-08-10 Morgan Adhesives Co. Method of making an adhesive construction
CN1030256A (zh) * 1987-06-29 1989-01-11 日清食品株式会社 检测和治疗人类免疫缺陷病毒的方法和物质
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5462863A (en) 1989-02-09 1995-10-31 Development Center For Biotechnology Isolation of Hepatitis B surface antigen from transformed yeast cells
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
WO1993007603A1 (en) 1991-10-04 1993-04-15 Cornett Robert H Approaching emergency vehicle warning system
WO1994002505A1 (en) 1992-07-20 1994-02-03 Duke University Compounds which inhibit hiv replication
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
CZ296649B6 (cs) 1993-02-23 2006-05-17 Genentech, Inc. Zpusob výroby stabilizovaného polypeptidového prostredku zahrnující stabilizování polypeptidu protidenaturaci organickými rozpoustedly, jeho príprava a prostredek pro regulované uvolnování polypeptidu
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
GB9404270D0 (en) 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US6004549A (en) 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
NZ311319A (en) 1995-06-07 2000-01-28 Trimeris Inc The treatment of HIV and other viral infections using the peptide DP-178 or DP-107 in combination therapy
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
EP1043030A4 (en) 1997-12-26 2007-05-02 Astellas Pharma Inc MEDICINAL COMPOSITIONS WITH PROLONGED RELEASE
JPH11209456A (ja) * 1998-01-29 1999-08-03 Hitachi Chem Co Ltd 印刷配線板用難燃性エポキシ樹脂組成物及びこれを用いたプリプレグ、金属箔張り積層板
US6281331B1 (en) 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
DE60000665T3 (de) 1999-05-17 2009-10-29 ConjuChem Biotechnologies Inc., Montreal Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
US6541020B1 (en) 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
AU5911101A (en) 2000-04-19 2001-10-30 Genentech Inc Sustained release formulations
IL159048A0 (en) 2001-06-21 2004-05-12 Genentech Inc Sustained release formulation
CN1100564C (zh) 2001-08-29 2003-02-05 周根发 用于治疗hiv感染的药物、其组合物及其用途
US7045552B2 (en) 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
AU2004313242A1 (en) * 2004-01-07 2005-07-28 Trimeris, Inc. HIV gp41 HR2-derived synthetic peptides, and their use in therapy to inhibit transmission of human immunodeficiency virus
JP2007529522A (ja) * 2004-03-15 2007-10-25 トリメリス，インコーポレーテッド ＨＩＶｇｐ４１由来ペプチドの部位特異的化学修飾
US9446139B2 (en) 2004-03-15 2016-09-20 Nektar Therapeutics Polymer-based compositions and conjugates of HIV entry inhibitors
DK1989220T3 (da) 2006-02-02 2012-04-02 Trimeris Inc HIV-fusionsinhibitorpeptider med forbedrede biologiske egenskaber

Similar Documents

Publication Publication Date Title
JP2009525051A5 (enExample)
Tilton et al. Entry inhibitors in the treatment of HIV-1 infection
IL281111A (en) Preparations for imparting resistance to viral diseases in social insects, and their use
WO2008045238A3 (en) Stabilized therapeutic small helical antiviral peptides
MY156951A (en) Micromirs
CL2007002610A1 (es) Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
CL2008001994A1 (es) Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras.
JP2007517055A5 (enExample)
EA201001529A1 (ru) Способ и композиция для лечения mif-опосредованных расстройств
DE502005006022D1 (de) Amphotere ethylmethacrylat-copolymere und deren verwendung
JP2010285439A5 (enExample)
JP2010059183A5 (enExample)
CL2008001620A1 (es) Induccion de fenotipo tolerogenico en celulas dendriticas maduras
WO2008006895A3 (en) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators
JP2010539123A5 (enExample)
JP2007520566A5 (enExample)
CL2007002689A1 (es) Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
CL2006002831A1 (es) Compuestos derivados de sulfonamida: proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad mediada por el receptor de glucocorticoides.
JP2011513399A5 (enExample)
EP3061824A3 (en) Organic compositions to treat beta-enac-related diseases
DK2178513T3 (da) Sammensætninger i tabletform indeholdende atazanavir
CL2008001563A1 (es) Compuestos derivados de benzodioxanos condensados con heterociclos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, crisis de panico, entre otras.
WO2010095858A3 (ko) 대황 추출물, 이의 분획물 또는 스틸벤계 화합물을 포함하는 세포간접착인자-1로 매개되는 질환의 예방 또는 치료용 약학적 조성물
IL177658A0 (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
AT8372U2 (de) Desmopressin umfassende zusammensetzung